Sleep represents an active phenomenon regulated by a highly integrated network of cortical and subcortical structures. This complex model results in disruptions at various levels during physiological aging and more deeply during neurodegenerative disorders, thus leading to different sleep alterations. In Alzheimer’s disease (AD), sleep-wake abnormalities were described to occur even in the preclinical phase, thus suggesting they could be a possible AD biomarker. On the other hand, they also favor the progression of the disease. In this paper, we review current theories regarding sleep regulations and functions to highlight the pathophysiological mechanisms at the basis of the bidirectional relationship between sleep and AD. A better understanding of these complex interactions might also be useful to target both sleep disorder management and AD-related symptoms.
GuarnieriB, SorbiS (2015) Sleep and cognitive decline: A strong bidirectional relationship. It Is time for specific recommendations on routine assessment and the management of sleep disorders in patients with mild cognitive impairment and dementia. Eur Neurol74, 43–48.
3.
VillaC, Ferini-StrambiL, CombiR (2015) The synergistic relationship between Alzheimer’s disease and sleep disorders: An update. J Alzheimers Dis46, 571–580.
4.
HopeT, KeeneJ, GedlingK, FairburnCG, JacobyR (1998) Predictors of institutionalization for people with dementia living at home with a carer. Int J Geriatr Psychiatry13, 682–690.
5.
YaffeK, FalveyCM, HoangT (2014) Connections between sleep and cognition in older adults. Lancet Neurol13, 1017–1028.
6.
RosenwasserAM (2009) Functional neuroanatomy of sleep and circadian rhythms. Brain Res Rev61, 281–306.
7.
BorbélyAA (1982) A two process model of sleep regulation. Hum Neurobiol1, 195–204.
8.
DaanS, BeersmaDG, BorbélyAA (1984) Timing of human sleep: Recovery process gated by a circadian pacemaker. Am J Physiol246, R161–183.
GolombekDA, RosensteinRE (2010) Physiology of circadian entrainment. Physiol Rev90, 1063–1102.
16.
HannibalJ, FahrenkrugJ (2006) Neuronal input pathways to the brain’s biological clock and their functional significance. Adv Anat Embryol Cell Biol182, 1–71.
17.
TakahashiJS, HongH-K, KoCH, McDearmonEL (2008) The genetics of mammalian circadian order and disorder: Implications for physiology and disease. Nat Rev Genet9, 764–775.
18.
SchmidtC, ColletteF, LeclercqY, SterpenichV, VandewalleG, BerthomierP, BerthomierC, PhillipsC, TinguelyG, DarsaudA, GaisS, SchabusM, DesseillesM, Dang-VuTT, SalmonE, BalteauE, DegueldreC, LuxenA, MaquetP, CajochenC, PeigneuxP (2009) Homeostatic sleep pressure and responses to sustained attention in the suprachiasmatic area. Science324, 516–519.
19.
ManderBA, WinerJR, WalkerMP (2017) Sleep and Human Aging. Neuron94, 19–36.
20.
CookeJR, Ancoli-IsraelS (2011) Normal and abnormal sleep in the elderly. Handb Clin Neurol98, 653–665.
21.
TouitouY (2001) Human aging and melatonin. Clinical relevance. Exp Gerontol36, 1083–1100.
22.
RaschB, BornJ (2013) About sleep’s role in memory. Physiol Rev93, 681–766.
23.
TononiG, CirelliC (2014) Sleep and the price of plasticity: From synaptic and cellular homeostasis to memory consolidation and integration. Neuron81, 12–34.
24.
de VivoL, BellesiM, MarshallW, BushongEA, EllismanMH, TononiG, CirelliC (2017) Ultrastructural evidence for synaptic scaling across the wake/sleep cycle. Science355, 507–510.
25.
BoyceR, GlasgowSD, WilliamsS, AdamantidisA (2016) Causal evidence for the role of REM sleep theta rhythm in contextual memory consolidation. Science352, 812–816.
26.
PeigneuxP, LaureysS, FuchsS, DestrebecqzA, ColletteF, DelbeuckX, PhillipsC, AertsJ, Del FioreG, DegueldreC, LuxenA, CleeremansA, MaquetP (2003) Learned material content and acquisition level modulate cerebral reactivation during posttraining rapid-eye-movements sleep. Neuroimage20, 125–134.
27.
MoroniF, NobiliL, CurcioG, De CarliF, TempestaD, MarzanoC, De GennaroL, MaiR, FrancioneS, Lo RussoG, FerraraM (2008) Procedural learning and sleep hippocampal low frequencies in humans. Neuroimage42, 911–918.
28.
FogelSM, SmithCT, CoteKA (2007) Dissociable learning-dependent changes in REM and non-REM sleep in declarative and procedural memory systems. Behav Brain Res180, 48–61.
29.
IliffJJ, WangM, LiaoY, PloggBA, PengW, GundersenGA, BenvenisteH, VatesGE, DeaneR, GoldmanSA, NagelhusEA, NedergaardM (2012) A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med4, 147ra111.
30.
LouveauA, Da MesquitaS, KipnisJ (2016) Lymphatics in neurological disorders: A neuro-lympho-vascular component of multiple sclerosis and Alzheimer’s disease?Neuron91, 957–973.
31.
JessenNA, MunkASF, LundgaardI, NedergaardM (2015) The glymphatic system: A beginner’s guide. Neurochem Res40, 2583–2599.
DuboisB, FeldmanHH, JacovaC, CummingsJL, DekoskyST, Barberger-GateauP, DelacourteA, FrisoniG, FoxNC, GalaskoD, GauthierS, HampelH, JichaGA, MeguroK, O’BrienJ, PasquierF, RobertP, RossorM, SallowayS, SarazinM, de SouzaLC, SternY, VisserPJ, ScheltensP (2010) Revising the definition of Alzheimer’s disease: A new lexicon. Lancet Neurol9, 1118–1127.
34.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
35.
HardyJ, SelkoeDJ (2002) The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science297, 353–356.
36.
Dá MesquitaS, FerreiraAC, SousaJC, Correia-NevesM, SousaN, MarquesF (2016) Insights on the pathophysiology of Alzheimer’s disease: The crosstalk between amyloid pathology, neuroinflammation and the peripheral immune system. Neurosci Biobehav Rev68, 547–562.
37.
BraakH, BraakE (1996) Evolution of the neuropathology of Alzheimer’s disease. Acta Neurol Scand Suppl165, 3–12.
38.
De StrooperB, KarranE (2016) The cellular phase of Alzheimer’s disease. Cell164, 603–615.
39.
Sanabria-CastroA, Alvarado-EcheverríaI, Monge-BonillaC (2017) Molecular pathogenesis of Alzheimer’s disease: An update. Ann Neurosci24, 46–54.
40.
MartoranaA, EspositoZ, KochG (2010) Beyond the cholinergic hypothesis: Do current drugs work in Alzheimer’s disease? Beyond the cholinergic hypothesis. CNS Neurosci Ther16, 235–245.
41.
ManderBA, WinerJR, JagustWJ, WalkerMP (2016) Sleep: A novel mechanistic pathway, biomarker, and treatment target in the pathology of Alzheimer’s disease?Trends Neurosci39, 552–566.
42.
KangDW, LeeCU, LimHK (2017) Role of sleep disturbance in the trajectory of Alzheimer’s disease. Clin Psychopharmacol Neurosci15, 89–99.
43.
TworogerSS, LeeS, SchernhammerES, GrodsteinF (2006) The association of self-reported sleep duration, difficulty sleeping, and snoring with cognitive function in older women. Alzheimer Dis Assoc Disord20, 41–48.
44.
JelicicM, BosmaH, PondsRWHM, Van BoxtelMPJ, HouxPJ, JollesJ (2002) Subjective sleep problems in later life as predictors of cognitive decline. Report from the Maastricht Ageing Study (MAAS). Int J Geriatr Psychiatry17, 73–77.
HatfieldCF (2004) Disrupted daily activity/rest cycles in relation to daily cortisol rhythms of home-dwelling patients with early Alzheimer’s dementia. Brain127, 1061–1074.
47.
MartinJ, MarlerM, ShochatT, Ancoli-IsraelS (2000) Circadian rhythms of agitation in institutionalized patients with Alzheimer’s disease. Chronobiol Int17, 405–418.
48.
VolicerL, HarperDG, ManningBC, GoldsteinR, SatlinA (2001) Sundowning and circadian rhythms in Alzheimer’s disease. Am J Psychiatry158, 704–711.
49.
RaggiA, NeriW, FerriR (2015) Sleep-related behaviors in Alzheimer’s disease and dementia with Lewy bodies. Rev Neurosci26, 31–38.
50.
CooganAN, SchutováB, HusungS, FurczykK, BauneBT, KroppP, HäßlerF, ThomeJ (2013) The circadian system in Alzheimer’s disease: Disturbances, mechanisms, and opportunities. Biol Psychiatry74, 333–339.
51.
WuY-H, FeenstraMGP, ZhouJ-N, LiuR-Y, ToranõJS, Van KanHJM, FischerDF, RavidR, SwaabDF (2003) Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: Alterations in preclinical and clinical stages. J Clin Endocrinol Metab88, 5898–5906.
52.
ZhouJ-N, LiuR-Y, KamphorstW, HofmanMA, SwaabDF (2003) Early neuropathological Alzheimer’s changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res35, 125–130.
53.
MoschosMM, MarkopoulosI, ChatziralliI, RouvasA, PapageorgiouSG, LadasI, VassilopoulosD (2012) Structural and functional impairment of the retina and optic nerve in Alzheimer’s disease. Curr Alzheimer Res9, 782–788.
54.
Koronyo-HamaouiM, KoronyoY, LjubimovAV, MillerCA, KoMK, BlackKL, SchwartzM, FarkasDL (2011) Identification of amyloid plaques in retinas from Alzheimer’s patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage54(Suppl 1), S204–217.
55.
La MorgiaC, Ross-CisnerosFN, KoronyoY, HannibalJ, GallassiR, CantalupoG, SambatiL, PanBX, TozerKR, BarboniP, ProviniF, AvanziniP, CarbonelliM, PelosiA, ChuiH, LiguoriR, BaruzziA, Koronyo-HamaouiM, SadunAA, CarelliV (2016) Melanopsin retinal ganglion cell loss in Alzheimer disease: mRGC Loss in AD. Ann Neurol79, 90–109.
56.
CermakianN, LamontEW, BoudreauP, BoivinDB (2011) Circadian clock gene expression in brain regions of Alzheimer ’s disease patients and control subjects. J Biol Rhythms26, 160–170.
57.
VitielloMV, PrinzPN, WilliamsDE, FrommletMS, RiesRK (1990) Sleep disturbances in patients with mild-stage Alzheimer’s disease. J Gerontol45, M131–M138.
58.
BomboisS, DerambureP, PasquierF, MonacaC (2010) Sleep disorders in aging and dementia. J Nutr Health Aging14, 212–217.
59.
MaestriM, CarnicelliL, TognoniG, Di CoscioE, GiorgiFS, VolpiL, EconomouN-T, KtonasP, FerriR, BonuccelliU, BonanniE (2015) Non-rapid eye movement sleep instability in mild cognitive impairment: A pilot study. Sleep Med16, 1139–1145.
60.
McCurrySM, ReynoldsCF, Ancoli-IsraelS, TeriL, VitielloMV (2000) Treatment of sleep disturbance in Alzheimer’s disease. Sleep Med Rev4, 603–628.
61.
BonanniE, Di CoscioE, MaestriM, CarnicelliL, TsekouH, EconomouNT, PaparrigopoulosT, BonakisA, PapageorgiouSG, VassilopoulosD, SoldatosCR,
MurriL,
KtonasPY (2012) Differences in EEG delta frequency characteristics and patterns in slow-wave sleep between dementia patients and controls: A pilot study. J Clin Neurophysiol29, 50–54.
62.
GorgoniM, LauriG, TrugliaI, CordoneS, SarassoS, ScarpelliS, MangiarugaA, D’AtriA, TempestaD, FerraraM, MarraC, RossiniPM, De GennaroL (2016) Parietal fast sleep spindle density decrease in Alzheimer’s disease and amnesic mild cognitive impairment. Neural Plast2016, 1–10.
63.
BrayetP, PetitD, FrauscherB, GagnonJ-F, GosselinN, GagnonK, RouleauI, MontplaisirJ (2016) Quantitative EEG of rapid-eye-movement sleep: A marker of amnestic mild cognitive impairment. Clin EEG Neurosci47, 134–141.
64.
RedaF, GorgoniM, LauriG, TrugliaI, CordoneS, ScarpelliS, MangiarugaA, D’AtriA, FerraraM, LacidognaG, MarraC, RossiniPM, De GennaroL (2017) In search of sleep biomarkers of Alzheimer’s disease: K-complexes do not discriminate between patients with mild cognitive impairment and healthy controls. Brain Sci7, 51.
65.
LimASP, EllisonBA, WangJL, YuL, SchneiderJA, BuchmanAS, BennettDA, SaperCB (2014) Sleep is related to neuron numbers in the ventrolateral preoptic/intermediate nucleus in older adults with and without Alzheimer’s disease. Brain137, 2847–2861.
66.
GrotheM, ZaborszkyL, AtienzaM, Gil-NecigaE, Rodriguez-RomeroR, TeipelSJ, AmuntsK, Suarez-GonzalezA, CanteroJL (2010) Reduction of basal forebrain cholinergic system parallels cognitive impairment in patients at high risk of developing Alzheimer’s disease. Cereb Cortex20, 1685–1695.
67.
PepeuG, Grazia GiovanniniM (2017) The fate of the brain cholinergic neurons in neurodegenerative diseases. Brain Res1670, 173–184.
68.
GuarnieriB, AdorniF, MusiccoM, AppollonioI, BonanniE, CaffarraP, CaltagironeC, CerroniG, ConcariL, CosentinoFII, FerraraS, FermiS, FerriR, GelosaG, LombardiG, MazzeiD, MearelliS, MorroneE, MurriL, NobiliFM, PasseroS, PerriR, RocchiR, SucapaneP, TognoniG, ZabberoniS, SorbiS (2012) Prevalence of sleep disturbances in mild cognitive impairment and dementing disorders: A multicenter italian clinical cross-sectional study on 431 patients. Dement Geriatr Cogn Disord33, 50–58.
69.
SperlingRA, AisenPS, BeckettLA, BennettDA, CraftS, FaganAM, IwatsuboT, JackCR, KayeJ, MontineTJ, ParkDC, ReimanEM, RoweCC, SiemersE, SternY, YaffeK, CarrilloMC, ThiesB, Morrison-BogoradM, WagsterMV, PhelpsCH (2011) Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 280–292.
ShiL, ChenS-J, MaM-Y, BaoY-P, HanY, WangY-M, ShiJ, VitielloMV, LuL (2017) Sleep disturbances increase the risk of dementia: A systematic review and meta-analysis. Sleep Med Rev, doi: 10.1016/j.smrv.2017.06.010
72.
JaussentI, BouyerJ, AncelinM-L, BerrC, Foubert-SamierA, RitchieK, OhayonMM, BessetA, DauvilliersY (2012) Excessive sleepiness is predictive of cognitive decline in the elderly. Sleep35, 1201–1207.
73.
KeageHAD, BanksS, YangKL, MorganK, BrayneC, MatthewsFE (2012) What sleep characteristics predict cognitive decline in the elderly?Sleep Med13, 886–892.
74.
GabelleA, GutierrezL-A, JaussentI, NavucetS, GrasselliC, BennysK, MarelliC, DavidR, AndrieuS, BerrC, VellasB, DauvilliersY (2017) Excessive sleepiness and longer nighttime in bed increase the risk of cognitive decline in frail elderly subjects: The MAPT-Sleep Study. Front Aging Neurosci9, 312.
75.
SprecherKE, BendlinBB, RacineAM, OkonkwoOC, ChristianBT, KoscikRL, SagerMA, AsthanaS, JohnsonSC, BencaRM (2015) Amyloid burden is associated with self-reported sleep in nondemented late middle-aged adults. Neurobiol Aging36, 2568–2576.
76.
CedernaesJ, OsorioRS, VargaAW, KamK, SchiöthHB, BenedictC (2017) Candidate mechanisms underlying the association between sleep-wake disruptions and Alzheimer’s disease. Sleep Med Rev31, 102–111.
77.
KangJ-E, LimMM, BatemanRJ, LeeJJ, SmythLP, CirritoJR, FujikiN, NishinoS, HoltzmanDM (2009) Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science326, 1005–1007.
78.
BatemanRJ, WenG, MorrisJC, HoltzmanDM (2007) Fluctuations of CSF amyloid-beta levels: Implications for a diagnostic and therapeutic biomarker. Neurology68, 666–669.
79.
BloomGS (2014) Amyloid-β and tau: The trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol71, 505–508.
80.
Di MecoA, JoshiYB, PraticòD (2014) Sleep deprivation impairs memory, tau metabolism, and synaptic integrity of a mouse model of Alzheimer’s disease with plaques and tangles. Neurobiol Aging35, 1813–1820.
81.
RothmanSM, HerdenerN, FrankolaKA, MughalMR, MattsonMP (2013) Chronic mild sleep restriction accentuates contextual memory impairments, and accumulations of cortical Aβ and pTau in a mouse model of Alzheimer’s disease. Brain Res1529, 200–208.
82.
CanteroJL, Hita-YañezE, Moreno-LopezB, PortilloF, RubioA, AvilaJ (2010) Tau protein role in sleep-wake cycle. J Alzheimers Dis21, 411–421.
83.
SprecherKE, KoscikRL, CarlssonCM, ZetterbergH, BlennowK, OkonkwoOC, SagerMA, AsthanaS, JohnsonSC, BencaRM, BendlinBB (2017) Poor sleep is associated with CSF biomarkers of amyloid pathology in cognitively normal adults. Neurology89, 445–453.
84.
GalloneS, BoschiS, RubinoE, De MartinoP, ScarpiniE, GalimbertiD, FenoglioC, AcutisPL, ManiaciMG, PinessiL, RaineroI (2014) Is HCRTR2 a genetic risk factor for Alzheimer’s disease?Dement Geriatr Cogn Disord38, 245–253.
85.
SlatsD, ClaassenJAHR, LammersGJ, MelisRJ, VerbeekMM, OvereemS (2012) Association between hypocretin-1 and amyloid-β42 cerebrospinal fluid levels in Alzheimer’s disease and healthy controls. Curr Alzheimer Res9, 1119–1125.
86.
LiguoriC, RomigiA, NuccetelliM, ZanninoS, SancesarioG, MartoranaA, AlbaneseM, MercuriNB, IzziF, BernardiniS, NittiA, SancesarioGM, SicaF, MarcianiMG, PlacidiF (2014) Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease. JAMA Neurol71, 1498.
87.
LiguoriC, NuccetelliM, IzziF, SancesarioG, RomigiA, MartoranaA, AmorosoC, BernardiniS, MarcianiMG, MercuriNB, PlacidiF (2016) Rapid eye movement sleep disruption and sleep fragmentation are associated with increased orexin-A cerebrospinal-fluid levels in mild cognitive impairment due to Alzheimer’s disease. Neurobiol Aging40, 120–126.
88.
FronczekR, van GeestS, FrölichM, OvereemS, RoelandseFWC, LammersGJ, SwaabDF (2012) Hypocretin (orexin) loss in Alzheimer’s disease. Neurobiol Aging33, 1642–1650.
89.
IshiiT (1966) Distribution of Alzheimer’s neurofibrillary changes in the brain stem and hypothalamus of senile dementia. Acta Neuropathol (Berl)6, 181–187.
90.
KasanukiK, IsekiE, KondoD, FujishiroH, MinegishiM, SatoK, KatsuseO, HinoH, KosakaK, AraiH (2014) Neuropathological investigation of hypocretin expression in brains of dementia with Lewy bodies. Neurosci Lett569, 68–73.
91.
GuarnieriB, MusiccoM, CaffarraP, AdorniF, AppollonioI, ArnaldiD, BartoliA, BonanniE, BonuccelliU, CaltagironeC, CerroniG, ConcariL, CosentinoFII, FermiS, FerriR, GelosaG, LombardiG, MearelliS, NobiliF, PasseroS, PerriR, RocchiR, SucapaneP, TognoniG, ZabberoniS, SorbiS (2014) Recommendations of the Sleep Study Group of the Italian Dementia Research Association (SINDem) on clinical assessment and management of sleep disorders in individuals with mild cognitive impairment and dementia: A clinical review. Neurol Sci35, 1329–1348.
92.
OomsS, JuY-E (2016) Treatment of sleep disorders in dementia. Curr Treat Options Neurol18, 40.
93.
UrrestarazuE, IriarteJ (2016) Clinical management of sleep disturbances in Alzheimer’s disease: Current and emerging strategies. Nat Sci Sleep8, 21–33.
94.
BrownCA, BerryR, TanMC, KhoshiaA, TurlapatiL, SwedloveF (2013) A critique of the evidence base for non-pharmacological sleep interventions for persons with dementia. Dementia12, 210–237.
95.
McCurrySM, LaFaziaDM, PikeKC, LogsdonRG, TeriL (2012) Development and evaluation of a sleep education program for older adults with dementia living in adult family homes. Am J Geriatr Psychiatry20, 494–504.
96.
OuslanderJG, ConnellBR, BliwiseDL, EndeshawY, GriffithsP, SchnelleJF (2006) A nonpharmacological intervention to improve sleep in nursing home patients: Results of a controlled clinical trial. J Am Geriatr Soc54, 38–47.
97.
ForbesD, BlakeCM, ThiessenEJ, PeacockS, HawranikP (2014) Light therapy for improving cognition, activities of daily living, sleep, challenging behaviour, and psychiatric disturbances in dementia. In Cochrane Database of Systematic Reviews, The Cochrane Collaboration, ed. John Wiley & Sons, Ltd, Chichester, UK.
98.
McCleeryJ, CohenDA, SharpleyAL (2015) Pharmacotherapies for sleep disturbances in Alzheimer’s disease. BJPscyh Adv21, 218–218.
99.
WyattJK, DijkD-J, Ritz-de CeccoA, RondaJM, CzeislerCA (2006) Sleep-facilitating effect of exogenous melatonin in healthy young men and women is circadian-phase dependent. Sleep29, 609–618.
100.
CardinaliDP, VigoDE, OlivarN, VidalMF, FurioAM, BruscoLI (2012) Therapeutic application of melatonin in mild cognitive impairment. Am J Neurodegener Dis1, 280–291.
101.
XuJ, WangL-L, DammerEB, LiC-B, XuG, ChenS-D, WangG (2015) Melatonin for sleep disorders and cognition in dementia: A meta-analysis of randomized controlled trials. Am J Alzheimers Dis Other Demen30, 439–447.
102.
Riemersma-van der LekRF, SwaabDF, TwiskJ, HolEM, HoogendijkWJG, Van SomerenEJW (2008) Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: A randomized controlled trial. JAMA299, 2642–2655.
103.
ZhangW, ChenX, SuS, JiaQ, DingT, ZhuZ, ZhangT (2016) Exogenous melatonin for sleep disorders in neurodegenerative diseases: A meta-analysis of randomized clinical trials. Neurol Sci37, 57–65.
104.
WadeAG, CrawfordG, FordI, McConnachieA, NirT, LaudonM, ZisapelN (2011) Prolonged release melatonin in the treatment of primary insomnia: Evaluation of the age cut-off for short- and long-term response. Curr Med Res Opin27, 87–98.
105.
WilsonSJ, NuttDJ, AlfordC, ArgyropoulosSV, BaldwinDS, BatesonAN, BrittonTC, CroweC, DijkD-J, EspieCA, GringrasP, HajakG, IdzikowskiC, KrystalAD, NashJR, SelsickH, SharpleyAL, WadeAG (2010) British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol24, 1577–1601.
106.
ArbonEL, KnurowskaM, DijkD-J (2015) Randomised clinical trial of the effects of prolonged-release melatonin, temazepam and zolpidem on slow-wave activity during sleep in healthy people. J Psychopharmacol29, 764–776.
107.
LemoineP, NirT, LaudonM, ZisapelN (2007) Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res16, 372–380.
108.
OtmaniS, DemazièresA, StanerC, JacobN, NirT, ZisapelN, StanerL (2008) Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. Hum Psychopharmacol23, 693–705.
109.
OtmaniS, MetzgerD, GuichardN, DanjouP, NirT, ZisapelN, KatzA (2012) Effects of prolonged-release melatonin and zolpidem on postural stability in older adults. Hum Psychopharmacol27, 270–276.
110.
WadeAG, FarmerM, HarariG, FundN, LaudonM, NirT, Frydman-MaromA, ZisapelN (2014) Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer’s disease: A 6-month, randomized, placebo-controlled, multicenter trial. Clin Interv Aging9, 947–961.
111.
CamargosEF, LouzadaLL, QuintasJL, NavesJOS, LouzadaFM, NóbregaOT (2014) Trazodone improves sleep parameters in Alzheimer disease patients: A randomized, double-blind, and placebo-controlled study. Am J Geriatr Psychiatry22, 1565–1574.
